Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
Date:11/7/2008

Pivotal Phase III Trial Primary Endpoints Achieved for SCOLR's 12-Hour

Ibuprofen

BOTHELL, Wash., Nov. 7 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) today reported financial results for the three and nine months ended September 30, 2008. The Company will host a live conference call today, November 7, 2008, at 11:30 a.m. (Eastern Standard Time).

Daniel O. Wilds, SCOLR Pharma's President and CEO, said, "We had a very productive third quarter making significant progress advancing our lead product candidates and securing additional non-dilutive operating capital while maintaining financial discipline. Most importantly, yesterday we reported favorable top-line results from our pivotal Phase III trial to evaluate the safety and efficacy of our 12 hour CDT(R) 600 mg extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The trial incorporated FDA special protocol assessment design elements, met both co-primary endpoints (p<0.0001), and had no significant adverse events. This successful trial is an extremely important milestone for the Company. We expect that the successful results of this study will focus the attention of potential partners and facilitate an alliance for our lead product candidate."

Also during the quarter, SCOLR submitted an Abbreviated New Drug Application (ANDA) for a 120 milligram 12-hour pseudoephedrine tablet based on our patented Controlled Delivery Technology (CDT(R)) platform. Subsequently, we reported that the U.S. FDA had accepted our submission for review. This is the first product approval application filed by SCOLR Pharma, and, if approved, would further demonstrate the novel advantages of our proprietary drug delivery technology. '/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
3. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
4. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... (CAS 103-90-2) Market Research Report 2014" report to ... Market Research Report 2014 presents comprehensive data on paracetamol ... , Asia , North ... includes paracetamol (acetaminophen) description, covers its application areas and ...
(Date:9/15/2014)... 15, 2014  MedExpress Urgent Care, a national leader in ... flu shots for ages four and up at each of ... get their flu shot early. According to ... of June, making late summer and early fall an ideal ... Vice President of Provider and Clinical Quality, Thomas Pangburn ...
(Date:9/15/2014)... PLYMOUTH MEETING, Pa. , Sept. 15, 2014 /PRNewswire/ ... today that it has met the stringent listing criteria ... has transferred to this U.S. stock exchange from the ... its current ticker symbol, "INO." NASDAQ ... Market, maintains the highest initial listing standards of any ...
Breaking Medicine Technology:Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 3MedExpress Quotes Late Summer, Early Fall As Best Time to Receive Flu Shot 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 3
... TOPAZ Technologies, a leading provider of biomedical research ... ML Weekes & Company, a professional services firm ... strategic partnership.  As a result of this partnership, ... solution through ML Weekes & Company,s RAMS grantsERA ...
... Texas, Nov. 16, 2010 Argon Medical Devices, Inc. ... licensing agreement with Rex Medical, LP ("Rex Medical") for ... dialysis catheter ™ on a global basis. UltraStream ™ ... patients receiving dialysis treatments. Argon will be ...
Cached Medicine Technology:TOPAZ Technologies and ML Weekes & Company Announce Partnership 2TOPAZ Technologies and ML Weekes & Company Announce Partnership 3Argon Medical Devices Announces Exclusive License and Distribution Agreement for 'UltraStream™' Chronic Hemodialysis Catheter 2
(Date:9/16/2014)... September 16, 2014 The Fertility Centers ... with Fairfax Egg Bank. The collaboration will give patients ... donor egg offering at the Fertility Centers of New ... and offers the nation’s largest selection of frozen donor ... several reasons:, , The Donor is ...
(Date:9/15/2014)... 16, 2014 The team of defective ... Danis & Lowe report that the company behind ... responsible for the injuries that a woman sustained after ... stress urinary incontinence (SUI). , Carey Danis & Lowe ... litigation and personal injury law. The St. Louis law ...
(Date:9/15/2014)... Phoenix, AZ (PRWEB) September 16, 2014 ... Law group in Phoenix Arizona announces one flat attorney ... in ensuring that clients retain the largest portion possible ... cover medical expenses, lost wages and damaged personal property. ... fee promise” to clients that simply states that no ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 1Heart ... training for most staff of Regency Park Oak ... collaboration with their Executive Director Gladys Broxton. This ... and initiative of 1Heart Shirley Billedo and Regency ... Artiga, Marketing Director Jeanine Hernandez and Activities Coordinator ...
(Date:9/15/2014)... 2014 Aging skin inevitably wrinkles, thins and ... is loss of collagen production. By age 60, skin ... to this slow down. Collagen holds up skin structure. , ... be boosted. There are several ways to do this, but ... cells (non-embryonic). , "The cost is higher than other types ...
Breaking Medicine News(10 mins):Health News:FCNE Announces Partnership with Fairfax Egg Bank 2Health News:Carey Danis & Lowe Reports On $73 Million Boston Scientific Verdict 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 3Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 2Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 3Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 4Health News:A Superior Way to Make Skin Younger and Assure Continual Collagen Production, from Sublime Beauty® 2
... use vitamin supplements for good health despite the fact that ... argues that the best way to stay healthy is a ... because they're worried that food has fewer nutrients than it ... and minerals is freshly picked produce, reported the online edition ...
... will be served at the domestic theme parks of the ... sign movie// and other endorsement deals only with restaurants that ... ,Disney will put the new guidelines into practice ... of 2007, the trans-fats will be completely removed from the ...
... lung disease; Chronic Obstructive Pulmonary Disease (COPD) will affect ... ,Chronic bronchitis and emphysema constitute COPD, which is ... fatigue, shortness of breath and subsequent difficulty in breathing ... at the Hvidovre Hospital in Denmark conducted a 25-year ...
... new study by researchers at Northwestern University has revealed a ... a U.S. regional poison control// center from 2001 through 2004, ... years. , ,Lead researcher Danielle McCarthy said “This study ... abuse. Part of the problem is that people do not ...
... child’s susceptibility to autism is increased with a single gene ... ,This discovery has far-reaching implications because this gene, a ... specifically a brain gene but rather a gene which has ... immune function and gut repair. ,Therefore researchers have ...
... Palmieri, of Imperial College London, on a small group of ... of Vitamin D with the progression of breast cancer to ... of circulating Vitamin D could play a significant role in ... tests of the women who underwent the study have shown ...
Cached Medicine News:Health News:Madhya Pradesh Tops in Implementing Child Health Scheme 2Health News:Risk of Autism doubled with Single Gene Mutation 2
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
eValuator fixed-curve diagnostic electrophysiology catheters offer an effective balance between clinical performance and cost....
... Two high performance technologies - Quantum™ ... shaft platform - unite in the ... a high dilatation force balloon with ... Laser bonded Maverick® shaft technology improves ...
Medicine Products: